DUS1L antibody
- Known as:
- DUS1L (anti-)
- Catalog number:
- orb30533
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- DUS1L antibody
Related genes to: DUS1L antibody
- Gene:
- DUS1L NIH gene
- Name:
- dihydrouridine synthase 1 like
- Previous symbol:
- -
- Synonyms:
- PP3111, DUS1
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-05-05
- Date modifiied:
- 2016-02-15
Related products to: DUS1L antibody
Related articles to: DUS1L antibody
- Human cytoplasmic tRNAs contain dihydrouridine modifications at positions 16 and 17 (D16/D17). The enzyme responsible for D16/D17 formation and its cellular roles remain elusive. Here, we identify DUS1L as the human tRNA D16/D17 writer. DUS1L knockout in the glioblastoma cell lines LNZ308 and U87 causes loss of D16/D17. D formation is reconstituted in vitro using recombinant DUS1L in the presence of NADPH or NADH. DUS1L knockout/overexpression in LNZ308 cells shows that DUS1L supports cell growth. Moreover, higher DUS1L expression in glioma patients is associated with poorer prognosis. Upon vector-mediated DUS1L overexpression in LNZ308 cells, 5' and 3' processing of precursor tRNA is inhibited, resulting in a reduced mature tRNA level, reduced translation of the tyrosine codons UAC and UAU, and reduced translational readthrough of the near-cognate stop codons UAA and UAG. Moreover, DUS1L overexpression increases the amounts of several D16/D17-containing tRNAs and total cellular translation. Our study identifies a human dihydrouridine writer, providing the foundation to study its roles in health and disease. - Source: PubMed
Publication date: 2024/10/02
Matsuura JinAkichika ShinichiroWei Fan-YanSuzuki TsutomuYamamoto TakahiroWatanabe YukaValášek Leoš ShivayaMukasa AkitakeTomizawa KazuhitoChujo Takeshi - RNA contains more than 170 types of chemical modifications, and these modified nucleosides are recognized, installed and removed by their reader, writer, and eraser (RWE) proteins, respectively. Here, we employed a parallel-reaction monitoring (PRM)-based targeted proteomic method, in conjunction with stable isotope labeling by amino acids in cell culture (SILAC), to examine comprehensively the differential expression of epitranscriptomic RWE proteins in a matched pair of primary/metastatic colorectal cancer (CRC) cells, namely SW480/SW620. We were able to quantify 113 nonredundant epitranscriptomic RWE proteins; among them, 48 and 5 were up- and down-regulated by >1.5-fold in SW620 over SW480 cells, respectively. Some of those proteins with marked up-regulation in metastatic CRC cells, including NAT10, hnRNPC, and DKC1, were documented to assume important roles in the metastasis of CRC and other types of cancer. Interrogation of the Clinical Proteomic Tumor Analysis Consortium data revealed the involvement of DUS1L in the initiation and metastatic transformation of CRC. It can be envisaged that the PRM method can be utilized, in the future, to identify epitranscriptomic RWE proteins involved in the metastatic transformations of other types of cancer. - Source: PubMed
Publication date: 2022/04/26
Qi Tianyu FTang FengYin JiekaiMiao WeiliWang Yinsheng